Haegarda(C1 esterase inhibitor (human))
HAEGARDA 2000 UNT Injection
NO BOXED WARNING
Dosage & Administration
Dosage & Administration
drug label
Haegarda Prescribing Information
financial assistance
Haegarda Financial Assistance Options
patient education
Haegarda Patient Education
Getting started on Haegarda
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
people also ask
Haegarda FAQs
1. Is it safe to use HAEGARDA during pregnancy?There are no prospective clinical data from HAEGARDA use in pregnant women. However, limited retrospective data suggest that C1-INH treatment during pregnancy did not lead to adverse events. The estimated background risk of birth defects and miscarriage in the general U.S. population is 2-4% and 15-20%, respectively.
2. What is known about HAEGARDA use during lactation?There is no information available about the presence of HAEGARDA in human milk, its impact on breastfed infants, or its effects on milk production. The decision to breastfeed should consider the benefits of breastfeeding and the mother's clinical need for HAEGARDA, while also evaluating potential adverse effects on the breastfed infant.
3. Has HAEGARDA been tested in pediatric patients?Yes, the safety and effectiveness of HAEGARDA were evaluated in a subgroup of patients aged 8 to <17 years in clinical trials, and the results were consistent with overall study results.
4. Is HAEGARDA suitable for use in geriatric patients?Clinical studies of HAEGARDA did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently from younger subjects. However, reported clinical experience has not identified differences in responses between the elderly and younger patients. Dosing for elderly patients should be cautious and typically start at the lower end of the dosing range, considering factors like decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapies.
FAQ Data Source